ArticlePloS one2017
Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Scoping Review and Meta-Analysis Suggests thatCannabis and cannabinoid research · 2021Pooled it
- The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review.Current neuropharmacology · 2021Pooled it
- Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.European journal of gastroenterology & hepatology · 2019Pooled it
- Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options.Current hepatology reports · 2026Review
- Cannabis produces acute hyperphagia in humans and rodents via increased reward valuation for, and motivation to, acquire food.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Cannabinoid System as a Potential Novel Target for Alcohol-Associated Liver Disease: A Propensity-Matched Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Hepatic CB1 receptor signaling triggers GMetabolism: clinical and experimental · 2025Article
- Review
- The Effect of Oil-Based Cannabis Extracts on Metabolic Parameters and Microbiota Composition of Mice Fed a Standard and a High-Fat Diet.International journal of molecular sciences · 2024Article
- The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice.International journal of molecular sciences · 2023Article
- Factors associated with hospitalizations for co-occurring HIV and opioid-related diagnoses: Evidence from the national inpatient sample, 2009-2017.Preventive medicine reports · 2023Article
- Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns.World journal of clinical cases · 2023Review
- Nutritional and Lifestyle Therapy for NAFLD in People with HIV.Nutrients · 2023Review
- Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?Cannabis and cannabinoid research · 2023Article
- Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.PloS one · 2023Article
- Article
- Cannabinoids and Chronic Liver Diseases.International journal of molecular sciences · 2022Review
- Review
- THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet.Journal of cannabis research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis use is associated with reduced prevalence of obesity and diabetes mellitus (DM) in humans and mouse disease models. Obesity and DM are a well-established independent risk factor for non-alcoholic fatty liver disease (NAFLD), the most prevalent liver disease globally. The effects of cannabis use on NAFLD prevalence in humans remains ill-defined. Our objective is to determine the relationship between cannabis use and the prevalence of NAFLD in humans. We conducted a population-based case-control study of 5,950,391 patients using the 2014 Healthcare Cost and Utilization Project (HCUP), Nationwide Inpatient Survey (NIS) discharge records of patients 18 years and older. After identifying patients with NAFLD (1% of all patients), we next identified three exposure groups: non-cannabis users (98.04%), non-dependent cannabis users (1.74%), and dependent cannabis users (0.22%). We adjusted for potential demographics and patient related confounders and used multivariate logistic regression (SAS 9.4) to determine the odds of developing NAFLD with respects to cannabis use. Our findings revealed that cannabis users (dependent and non-dependent) showed significantly lower NAFLD prevalence compared to non-users (AOR: 0.82[0.76-0.88]; p<0.0001). The prevalence of NAFLD was 15% lower in non-dependent users (AOR: 0.85[0.79-0.92]; p<0.0001) and 52% lower in dependent users (AOR: 0.49[0.36-0.65]; p<0.0001). Among cannabis users, dependent patients had 43% significantly lower prevalence of NAFLD compared to non-dependent patients (AOR: 0.57[0.42-0.77]; p<0.0001). Our observations suggest that cannabis use is associated with lower prevalence of NAFLD in patients. These novel findings suggest additional molecular mechanistic studies to explore the potential role of cannabis use in NAFLD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.